En Es
Categories

Industry News


Stago Group Acquires HemoSonics

By Labmedica International staff writers
30 May 2017

Image: The Stago Group has acquired HemoSonics as part of ongoing efforts to diversify its portfolio of medical devices (Photo courtesy of iStock).The Stago Group, which develops and markets automated systems for blood analysis in coagulation, has completed the acquisition of HemoSonics LLC, a developer of point-of-care (POC) testing solutions.

Stago, a leading player in the in-vitro diagnostics industry, focuses on the exploration of thrombosis and hemostasis. HemoSonics, a medical device company, develops POC diagnostic platforms to guide the management of critical bleeding in order to improve outcomes and enable more targeted transfusion of blood products.

Stago’s acquisition of HemoSonics is a part of the company's on-going efforts to diversify its portfolio of medical devices. With the acquisition of HemoSonics’ patented SEER technology (Sonic Estimation of Elasticity via Resonance) and its associated Quantra hemostasis analyzer, Stago expects to further strengthen its position in the hemostasis testing market.

“This significant step makes us very proud to contribute to the management of healthcare costs and to the improvement of patients outcomes worldwide,” said Lionel Viret, Chairman of the Board, Stago Group.

“Stago brings exceptional expertise in the field of thrombosis and hemostasis that will greatly advance our efforts to rapidly and effectively deliver a new standard of care for the management of bleeding in the critical care setting,” said Timothy Fischer, President and Chief Executive Officer of HemoSonics.



E-mail Print
FaceBook Twitter Google+ Linked in

DIAGNOSTICA STAGO

Offers a complete system of hemostasis instrumentation and optimized reagent kits for research, as well as for routine analysis
Gold member
More info

More articles about DIAGNOSTICA STAGO

09 Aug 2018
Stago Connect.One Network Allows Remote Monitoring of Analyzers
Diagnostica Stago, an in-vitro diagnostics company focusing on thrombosis and hemostasis, has launched the secure Connect.One network architecture, which allows laboratories to benefit from remote monitoring of their automated analyzers.
Read More

Additional news

23 Nov 2018
AI Predicts Alzheimer’s Disease Years before Diagnosis
A new study on the application of deep learning (DL) to detect changes in brain metabolism predictive of Alzheimer’s disease (AD) has found that artificial intelligence (AI) improves the ability of brain imaging to predict AD.
Read More
23 Nov 2018
UK to Set Up New GBP 10 Million Centre for Medical Imaging and AI
The UK’s London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare will train sophisticated artificial intelligence (AI) algorithms from NHS medical images and patient data, to create tools that will help clinicians speed up and improve diagnosis and care across a number of patient pathways, including dementia, heart failure and cancer.
Read More
23 Nov 2018
New AI Algorithm Enhances Polyp Detection in Colonoscopy Procedures
Researchers at Shanghai Wision AI Co., Ltd., a developer of computer-aided diagnostic algorithms and systems to improve the accuracy and effectiveness of diagnostic imaging, have announced results of a study validating a novel machine-learning algorithm that improves detection of adenomatous polyps during colonoscopy. The AI algorithm is built on the same network architecture that is used to develop self-driving cars and is designed to enable “self-driving” in colonoscopy procedures.
Read More
20 Nov 2018
Study Finds AI Falls Short When Analyzing Medical Data
A study conducted at the Icahn School of Medicine at Mount Sinai has found that artificial intelligence (AI) tools trained to detect pneumonia on chest X-rays suffered significant decreases in performance when tested on data from outside health systems. These findings suggest that unless AI in the medical space is carefully tested for performance across a wide range of populations, the deep learning models may not perform as accurately as expected.
Read More
20 Nov 2018
New AI Software for Brain Bleed Diagnosis Receives FDA Clearance
The US Food and Drug Administration (FDA) has given 510(k) clearance to the Accipio Ix intracranial hemorrhage (ICH) detection software developed by MaxQ AI, a clinical diagnostics intelligence platform company.
Read More
20 Nov 2018
Global Refurbished Medical Devices Market to Increase by 10% by 2023
The global refurbished medical devices market is expected to grow at a CAGR of over 10% during the forecast period 2019-2023, driven by the organized healthcare ecosystem in the developed economies. Moreover, privatization in the healthcare sector is increasing rapidly due to the inability of governments to invest efficiently in the sector, coupled with high demand for innovation and technology for superior healthcare services.
Read More
12 Nov 2018
ACR Data Science Institute Releases AI Use Cases to Accelerate AI Adoption
The American College of Radiology Data Science Institute has released a first-of-its-kind series of standardized artificial intelligence (AI) use cases that will accelerate medical imaging AI adoption. This continually updated, freely available use case series is the product of a previously missing and collaborative framework that enables efficient creation, implementation and ongoing improvement of radiological AI tools.
Read More
12 Nov 2018
Siemens Healthineers and Primary Health Care Enter Contract for In Vitro Diagnostics
Siemens Healthineers has entered into a strategic partnership with Australian integrated healthcare provider Primary Health Care to deploy more than 70 Atellica Solution immunoassay and clinical chemistry analyzers, marking the largest contract ever for in vitro diagnostics testing in the country.
Read More
12 Nov 2018
OpenSight Augmented Reality System for Microsoft HoloLens Cleared by FDA
The FDA has granted 510(k) clearance to the OpenSight Augmented Reality System, making it the first AR medical solution for Microsoft HoloLens to be cleared for use in pre-operative surgical planning. Developed by Novarad, a provider of specialized enterprise imaging and workflow solutions, OpenSight renders 2D, 3D and 4D images of patients interactively, while accurately overlaying them directly onto the patient’s body.
Read More
Copyright © 2000-2018 TradeMed.com. All rights reserved. | Terms And Conditions